Apellis Pharmaceuticals
Subsidiary of Biogen (BIIB)
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Pegcetacoplan(Empaveli) | Approved | Complement C3Peptide | Complement-Mediated Renal DiseaseParoxysmal Nocturnal Hemoglobinuria |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
July 2027 (1)
Pegcetacoplan · EmpaveliPhase 3C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G) …
Est. primary completion 2027-07 · NCT05809531 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Est. primary completion 2028-12 · NCT04901936 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Pegcetacoplan · EmpaveliPhase 3C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) …
Est. primary completion 2031-01-17 · NCT07898774 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.